Stifel analyst Annabel Samimy notes that Bausch Health (BHC) entered into a "stalking horse" bid to acquire through bankruptcy proceedings substantially all of Synergy Pharmaceutical's (SGYP) GI assets, which includes rights to Trulance/plecanotide, dolcanatide and its intellectual property. While still subject to competitive bids, these assets "fit squarely" into Bausch Health's GI wheelhouse, which would immediately leverage the company's sales and payer infrastructure and physician relationships in the space, the analyst contends. Though competitive with Allergan's (AGN) Linzess, Bausch Health has proven a strong player in the GI space and she thinks it is exactly the presence needed to optimize/maximize sales of Trulance, with its strong efficacy and tolerability profile. Samimy reiterates a Buy rating and $35 price target on Bausch Health's shares.